JCM
TBPH icon

Jacobi Capital Management’s Theravance Biopharma TBPH Stock Holding History

Jacobi Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250
Closed -$5K – 1437
2021
Q1 		$5K Buy
+250
New +$4.75K ﹤0.01% 1126

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jacobi Capital Management's TBPH Position: Q2 2021 in Review

Jacobi Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2021, closing a stake of 250 shares — an estimated $5K sold.

Jacobi Capital Management first reported a position in TBPH in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 108 funds tracked by Wall St. Rank hold TBPH as of Q2 2021.

  • Jacobi Capital Management reported no remaining Theravance Biopharma position as of Q2 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 250 Theravance Biopharma shares in Q2 2021, an estimated $5K.
  • Jacobi Capital Management first reported a position in Theravance Biopharma in Q1 2021 and held it in 1 quarter.
  • Jacobi Capital Management's Theravance Biopharma position peaked at $5K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2021.

Based on Jacobi Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.